family with sequence similarity 131 member BGenealiases: []
Q-omics provides the consensus-scored FAM131B profile across patient tissues and cancer cell-line models. FAM131B expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, FAM131B is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, FAM131B RNA expression shows 17,402 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight SCLC, KICH, and THYM as cancer lineages where FAM131B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM131B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM131B survival associations across molecular data types. FAM131B RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM131B RNA expression–survival associations across cancer types. High FAM131B expression shows unfavorable associations in UVM, LUAD and MESO, but favorable associations in SCLC, SKCM and ESCA. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for FAM131B RNA expression.
This table summarizes FAM131B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for FAM131B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM131B shows lower tumor expression in KICH, UCEC, BLCA, KIRC and PRAD and higher tumor expression in LIHC. The KICH box plot shows higher FAM131B RNA expression in normal versus tumor tissue (log2 FC = −1.096, t-test p < 0.001).
This table shows molecular features associated with FAM131B in patient tissues and cancer cell lines. In patient samples, FAM131B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM131B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and LUNG_SCLC.
